Cytokinetics has begun a Phase 1 clinical trial for CK-4015089, a fast skeletal muscle troponin activator (FSTA).

Ascletis Pharma has completed enrollment of 480 patients in a Phase III clinical trial for ASC40 (denifanstat), an oral tablet for moderate to severe acne.

Sugemalimab, in combination with platinum-based chemotherapy, has been approved by the UK's MHRA for first-line treatment of metastatic non-small cell lung cancer (NSCLC).

Cytokinetics has begun a Phase 1 clinical trial of CK-4015089, a fast skeletal muscle troponin activator (FSTA).

The University of Alabama at Birmingham (UAB) has initiated the ADAPT clinical trial, focusing on adaptive treatment strategies for individuals experiencing early relapse after attempting to quit smoking.

A fentanyl vaccine developed at the University of Houston is set to enter clinical trials in mid-2025, aiming to prevent the opioid from reaching the brain.

Researchers have developed an implantable sensor for continuous, real-time monitoring of inflammation by tracking cytokine levels.

Russia has developed a personalized mRNA cancer vaccine, expected to be available to patients free of charge starting in early 2025.

The European Medicines Agency's CHMP has recommended approving six new biosimilars, expanding treatment options for various conditions.

GLP-1 agonists, initially developed for type 2 diabetes treatment, have shown significant efficacy in promoting weight loss in both preclinical and clinical studies. This review highlights the role of GLP-1 agonists in weight management, their pleiotropic effects, and their impact on hyperglycemia, insulin sensitivity, blood pressure, and cardio-metabolic and renal protection.

A new precision risk screening tool for prostate cancer, developed by a team of VA, academic, and industry researchers, is being tested in a clinical trial named ProGRESS. This tool aims to improve the accuracy of prostate cancer screening by using individual risk prediction based on family history and genetic markers, potentially reducing unnecessary procedures and addressing health disparities.

A recent study validates the ORACLE prognostic signature for lung adenocarcinoma (LUAD), demonstrating its effectiveness in predicting patient survival and its potential utility in guiding adjuvant therapy decisions. The research leverages multiregion RNA sequencing data from the TRACERx study, highlighting ORACLE's superior performance in tumor sampling bias assessment and its association with overall survival, lung-cancer-specific survival, and disease-free survival.

The FDA has approved Epsolay, a 5% encapsulated benzoyl peroxide cream, for treating inflammatory lesions of rosacea in adults.

Ethics Committees must ensure clinical trials involving children include experts knowledgeable in paediatric, ethical, clinical, and psychosocial issues, as highlighted by recent discussions on protocol deviations and conflicts of interest.

This article reviews the progress in clinical trials of oncolytic viruses (OVs) for cancer treatment, highlighting their safety, effectiveness, and the challenges faced in their development. OVs selectively infect and kill cancer cells without harming normal cells, showing promise in treating various tumors with mild adverse events.

A study published in RMD Open reveals that effective antirheumatic treatments, particularly tocilizumab, significantly improve hemostatic imbalances in newly diagnosed rheumatoid arthritis (RA) patients within the first 24 weeks, potentially reducing elevated thrombosis risks. The research highlights the importance of early treatment and the role of biological drugs in mitigating the procoagulant state in RA patients.

A clinical trial demonstrated that DAV132, a product containing activated charcoal, significantly reduces the exposure of the human gut microbiome to the antibiotic moxifloxacin (MXF) without affecting its plasma pharmacokinetics. The study, involving healthy volunteers, showed that DAV132 could protect the intestinal microbiota's richness and composition from the adverse effects of MXF, suggesting its potential to mitigate the long-term consequences of antibiotic treatments.

The FDA has delayed its decision on GSK's momelotinib, a potential treatment for myelofibrosis, to September 16 to review additional data.

Political changes in the UK and Europe may negatively impact university-based gene therapy research, while established pharmaceutical companies are expected to face minimal disruption in 2025.

Duke University researchers demonstrated that combining enzalutamide with standard hormonal therapy extends survival by 30% in men with metastatic prostate cancer.